Milroy Samuel, MD
Obstetrics & Gynecology · Columbus, OHNPI 1982647566
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Myovant Sciences Inc. accounts for 62.5% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2021 at $8,904 and has fallen 90.2% since, to $869 in 2025. Among obstetrics & gynecology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $50.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$11K
- USWM, LLC$719
- Tris Pharma Inc$552
- AbbVie$516
- Minerva Surgical, Inc$477
- Indivior Inc.$443
- plus $4K from 35 others
Across 82 payments — averaging $2322.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$85K
- Sumitomo Pharma America, Inc.$36K
- Evofem Biosciences, Inc.$29K
- Myovant Sciences GmbH$18K
- Bayer$10K
- Mitsubishi Tanabe Pharma Development America, Inc.$10K
- plus $3K from 1 others
What the payments were for
- Speaking & faculty fees$9,02052%
- Travel & lodging$6734%
- Food & beverage$7,69344%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myovant Sciences Inc. | 60 | $10,903 |
| USWM, LLC | 29 | $719 |
| Tris Pharma Inc | 32 | $552 |
| AbbVie | 33 | $516 |
| Minerva Surgical, Inc | 7 | $477 |
| Indivior Inc. | 22 | $443 |
| Axsome Therapeutics, Inc. | 13 | $441 |
| Corcept Therapeutics | 9 | $323 |
| Currax Pharmaceuticals LLC | 33 | $321 |
| Teva Pharmaceuticals USA, Inc. | 8 | $315 |
| Braeburn Inc. | 12 | $266 |
| Alkermes, Inc. | 4 | $233 |
| Lupin Inc. | 8 | $228 |
| Orexo US, Inc. | 14 | $215 |
| Redhill Biopharma Inc. | 6 | $197 |
| Astellas Pharma US Inc | 8 | $173 |
| Abbott | 1 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $121 |
| ZOLL Respicardia, Inc. | 1 | $111 |
| Novo Nordisk | 6 | $110 |
| AstraZeneca | 1 | $94 |
| Hikma Pharmaceuticals USA | 3 | $58 |
| Shield Therapeutics Inc | 3 | $47 |
| Exeltis, USA Inc. | 3 | $45 |
| Gilead | 2 | $45 |
| Lilly USA, LLC | 3 | $42 |
| Channel Medsystems, Inc. | 1 | $33 |
| Pear Therapeutics (US), Inc. | 2 | $32 |
| Intra-sana Laboratories | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| BD | 1 | $20 |
| Meditrina | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Athena Bioscience, LLC | 1 | $17 |
| MDD US Operations, LLC | 1 | $17 |
| Roche Diagnostics Corporation | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Medline Industries LP | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Vivus LLC | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$10,063
- LYBALVI$462
- Dyanavel XR$225
- Quillivant$225
- Quillichew ER$225
- ALERE$165
- SUBLOCADE$126
- Austedo XR$124
- Auvelity$121
- SOLOSEC$121
- AUSTEDO$111
- remede System$111
- Korlym$108
- Talicia$104
How this compares
$17,443 in reported general payments places this provider in the 95th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $1,622 |
| Atorvastatin Calcium | 22 | $57 |
| Amlodipine Besylate | 19 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $58 | $1,62220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Other obstetrics & gynecology in Columbus
- Erin OlahColumbus$97K
- David PortmanColumbus$94K
- Anita SomaniColumbus$93K
- Andrew BokorColumbus$35K
- Steven BalaloskiColumbus$20K
- Shivkamini SomasundaramColumbus$16K
- Rachel GilmanColumbus$11K
- Leah AdkinsColumbus$11K
- Samir AhujaMentor$430K
- Burton BrodskySylvania$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.